|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection显示文摘AIM:To evaluate the effects of tenofovir disoproxil fumarate(TDF)use during late pregnancy to reduce hepatitis B virus(HBV)transmission in highly viremic mothers.METHODS:This retrospective study included 45 pregnant patients with hepatitis B e antigen(+)chronic hepatitis B and HBV DNA levels>107copies/mL who received TDF 300 mg/d from week 18 to 27 of gestation(n=21).Untreated pregnant patients served as controls(n =24).All infants received 200 IU of hepatitis B immune globulin(HBIG)within 24 h postpartum and 20μg of recombinant HBV vaccine at 4,8,and 24 wk.Perinatal transmission rate was determined by hepatitis B surface antigen and HBV DNA results in infants at week 28.RESULTS:At week 28,none of the infants of TDFtreated mothers had immunoprophylaxis failure,whereas2(8.3%)of the infants of control mothers had immunoprophylaxis failure(P=0.022).There were no differences between the groups in terms of adverse events in mothers or congenital deformities,gestational age,height,or weight in infants.At postpartum week 28,significantly more TDF-treated mothers had levels of HBV DNA<250 copies/mL and normalized alanine aminotransferase compared with controls(62%vs none,P<0.001;82%vs 61%,P=0.012,respectively).CONCLUSION:TDF therapy during the second or third trimester reduced perinatal transmission rates of HBV and no adverse events were observed in mothers or infants. | Mustafa Kemal Celen Duygu Mert Müzeyyen Ay Tuba Dal Safak Kaya Necmettin Yildirim Serda Gulsun Tunga Barcin Sevgi Kalkanli Mehmet Sinan Dal Celal Ayaz | 2013 | World Journal of Gastroenterology2013，19，48： | 26 |
| 2 | Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study显示文摘AIM To make efficacy and safety comparison of telbivudineraodmap and tenofovir-roadmap in hepatitis B e antigen(HBe Ag)-negative chronic hepatitis B(CHB) patients.METHODS This was the first prospective, randomised, two-arm, open-label, non-inferiority study in HBe Ag-negative CHB patients that compared telbivudine and tenofovir administered as per roadmap concept. Patients were treated up to 24 wk and, depending on virologic response, continued the same therapy or received addon therapy up to 104 wk. Eligible patients received an additional 52 wk of treatment in the extension period(i.e., up to 156 wk). Patients who developed virologic breakthrough(VB) while on monotherapy also received add-on therapy. The primary efficacy endpoint was the rate of patients achieving hepatitis B virus(HBV) DNA < 300 copies/m L at week 52. Secondary efficacy endpoints included the rates of HBV DNA < 300 and < 169 copies/m L, HBV DNA change from baseline, alanine aminotransferase normalisation, hepatitis B surface antigen(HBs Ag) loss, HBs Ag seroconversion, VB, and emergence of resistance at various timepoints throughout the study. Safety and estimated glomerular filtration rate(e GFR) were also analysed.RESULTS A total of 241 patients were randomised. Non-inferiority of telbivudine arm to tenofovir arm was demonstrated at week 52(± 7 d window), with over 91% of patients in each treatment arm achieving HBV DNA level < 300 copies/m L. Both arms were similar in terms of key secondary efficacy variables at weeks 104 and 156. The percentage of patients achieving HBV DNA < 300 copies/m L remained high and was similar in the telbivudine and tenofovir arms at both weeks 104 and 156. Over 82% of patients in both arms achieved alanine aminotransferase normalisation at week 52, and this percentage remained high at weeks 104 and 156. Telbivudine treatment progressively reduced serum HBs Ag levels from baseline while no change was reported in quantitative HBs Ag during therapy with tenofovir. Both treaments showed acceptable safety profiles. The telbivudine arm showed e GFR improvement unlike the tenofovir arm.CONCLUSION Efficacy was shown for both telbivudine-roadmap and tenofovir-roadmap regimens in HBe Ag-negative CHB patients over 156 wk. Telbivudine arm was associated with renal improvement. | Zahari Krastev Diana Petrova Iskren Kotzev Mustafa Kemal Celen Meryl Mendelson Richa Chandra Priti Pandey Kamal Hamed | 2016 | World Journal of Hepatology2016，8，32： | 9 |
| 3 | Efficacy and safety of pegylated-interferon α-2a in hemodialysis patients with chronic hepatitis C显示文摘AIM: To evaluate the efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronichepatitis C.METHODS: Thirty-six hemodialysis patients with chronichepatitis C were enrolled in a controlled and prospectivestudy. All patients were treatment naive, positivetested for anti-HCV antibodies, and positive tested forserum HCV-RNA. Twenty-two patients received 135 μgpeglyated-interferon a-2a weekly for 48 wk (group A).The remaining patients were left untreated, elevenrefused therapy, and three were not candidates forkidney transplantation and were allocated to the controlgroup (group B). At the end of the treatment biochemicaland virological response was evaluated, and 24 wk aftercompletetion of therapy sustained virological response(SVR) was assessed. Side effects were monitored.RESULTS: Of 22 hemodialysis patients, 12 were maleand 10 female, with a mean age of 35.2 ± 12.1 years.Virological end-of-treatment response was observed in14 patients (82.4%) in group A and in one patient (7.1%)in group B (P = 0.001). Sustained virological responsewas observed in 11 patients (64.7%) in group A and inone patient in group B (7.1%). Biochemical responseparameters normalized in 10/14 patients (71.4%) at theend of the treatment. ALT levels in group B were initiallyhigh in six patients and normalized in one of them (25%)at the end of the 48 wk. In five patients (22.7%) therapyhad to be stopped at mo 4 due to complications ofweakness, anemia, and bleeding.CONCLUSION: SVR could be achieved in 64.7% ofpatients on hemodialysis with chronic hepatitis C by atreatment with peglyated-interferon a-2a. Group A hada significantly better efficacy compared to the controlgroup B, but the side effects need to be concerned. | Celal Ayaz Mustafa Kemal Celen Ugur Nedim Yuce Mehmet Faruk Geyik | 2008 | World Journal of Gastroenterology2008，14，2： | 5 |
| 4 | Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B显示文摘 | Ayaz C Celen MK Colak H | 2006 | Indian J Gastroenterol2006，25，： | 1 |
| 5 | Predictive value of umbilical artery Doppler for adveme perinatal outcome in patients with HELLP syndrome显示文摘 | Simsek Y Celen S Simsek A | 2013 | Eur Rev Med Pharmacol Sci2013，17，12： | 1 |
| 6 | Along-standing in comprehensible matter of obstetrics:meconium-stained amniotic fluid,a new approach to reason显示文摘 | Simsek A Celen S Islimye M | | 0，，： | 1 |
| 7 | The surgical management of incidental gallbladder carcinoma显示文摘 | Yildirim E Celen O Gulben K | 2005 | Eur J Surg Oncol2005，31，： | 1 |
| 8 | Correlation of vascular endothelial growth factor (VEGF) and CEA with clinicopathological variables in colorectal cancer patients显示文摘 | Celen O Kahraman I Yildirim E | 2004 | Neoplasma2004，51，4： | 1 |
| 9 | Effect of air assistance on deposition distribution on spraying by tunnel-type electrostatic sprayer显示文摘 | Ilker H Celen Mehmet R Durgut Gurkan G Avci | 2009 | African Journal of Agricultural Research2009，4，12： | 1 |
| 10 | Multiple muscle metastases from lung cancer detected by FDG PET/CT显示文摘 | Yilmaz M Elboga U Celen Z | | 0，，03： | 1 |
| 11 | and S显示文摘 | Celen B | | 0，，： | 1 |
| 12 | Recovery of ammonia as struvite from anaerobic digester effluents显示文摘 | Celen I Turker M | 2001 | Environment Technology2001，22，： | 1 |
| 13 | Correlation of vascular endothelial growth factor(VEGF) and CEA with clinicopatho- logical variables in eoloreetal cancer patients 显示文摘 | Celen O Kahraman I Yildirim E | 2004 | Neoplasma2004，51，4： | 1 |
| 14 | FDG PET-CT in cervical cancer:relationship between primary tumor FDG uptake and metastatic potential显示文摘 | Yilmaz M Adli M Celen Z | | 0，，： | 1 |
| 15 | Removal of uterine fibroids during cesarean section: a difficult therapeutic decision 显示文摘 | Simsek Y Celen S Danisman N | 2012 | Clin Exp Obstet Gynecol2012，39，： | 1 |
| 16 | Effect of laser welding parameters on fusion zone morphological, mechanical and microstructural characteristics of AISI304 stainless steel 显示文摘 | S Celen S Karadeniz H Ozden | 2008 | Materialwissenschaft und Werkstofftech2008，39，11： | 1 |
| 17 | Operation-dependent main- tenance scheduling in flexible manufacturing systems 显示文摘 | Celen M Djurdjanovic D | 2012 | CIRP Journal of Manufacturing Science and Technology2012，5，4： | 1 |
| 18 | Correlation of vascular endothelial growth factor (VEGF) and CEA with clinicopathological variables in colorectal cancer patients显示文摘 | Celen O Kahraman I Yildirim E | 2004 | Neoplasma2004，51，4： | 1 |
| 19 | A multivariate approach to the acetylated poplar wood samples by near infrared spectro-scopy显示文摘 | Celen I Harper D Labbe N | 2008 | Holzforschung2008，62，2： | 1 |
| 20 | Brucellosis is a major problem: A five years experience显示文摘 | DAL T CELEN MK AYAZ C | 2013 | Acta Medica Mediterranea2013，29，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员